T. Luna

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

G. Daniels, M. Morse, J. Dutcher, 2017, Journal of Immunotherapy for Cancer.

A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.

M. Ernstoff, M. Milhem, Joseph I. Clark, 2015 .

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

M. Ernstoff, B. Taback, J. Lutzky, 2018, Journal of Immunotherapy for Cancer.

Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab

D. Stein, A. Yarur, Anjali Jain, 2017 .

DOP020 Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab.

D. Stein, A. Yarur, K. Hester, 2017, Journal of Crohn's & colitis.